Abstract:Background: Targeted magnetic resonance contrast agents have enabled the imaging of biological processes in vivo, and current insights have opened up new perspectives for the monitoring and diagnosis of many diseases. Purpose: To develop a contrast agent for targeting somatostatin receptors (SSTRs) expressed on breast cancer cells, and to evaluate the detection capabilities of a molecular probe using magnetic resonance (MR) imaging in an in vivo mouse model of breast carcinoma. Material and Methods: Octreotide (OCT) was conjugated with polyethylene glycol-coated ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles by an ethyl-3-(dimethylaminopropyl) carbodiimide (EDC)-mediated reaction. Prussian blue staining for intracellular iron, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and cellular MR imaging in vitro were performed on labeled MCF-7 breast cancer cells. Twenty-four mice bearing tumors were divided into two groups: 1) study group with injection of OCT-USPIOs ( n=12); 2) control group with injection of USPIOs ( n=12). Tumors were monitored in vivo using a 3.0-Tesla MR scanner before and after injection of contrast agents, and the findings were correlated with the histopathological findings. Results: OCT-USPIOs were shown to specifically bind to MCF-7 cells and did not affect proliferation and viability of the cells labeled. T 2 value of the cells labeled with OCT-USPIOs in vitro was 56.465±13.147 ms, while those of the cells cultured with USPIOs and gelatin/phosphate-buffered saline (PBS) gel alone were 75.435±16.171 ms and 85.950±22.352 ms, respectively ( P<0.05). Signal intensity of the tumor gradually decreased, and its T 2 value reached a minimum of approximately 24.49% 6 hours after injection of OCT-USPIOs in vivo, compared to a minimum of 21.89% after 2 hours in the control group. Iron depositions were visualized as blue particles in tumor 6 hours after injection of OCT-USPIOs, while no blue particles were observed in the control group. Conclusion: SSTR expression in vitro and in vivo can be selectively and directly imaged with an MR molecular probe. OCT-conjugated PEG-coated USPIO is potentially suitable to be used as a magnetic resonance contrast agent for MR imaging in vivo and increases the sensitivity for the early detection of breast carcinoma.

Magnetic iron oxide particles coated with carboxydextran for parenteral administration and liver contrasting. Pre-clinical profile of SH U555A

Ultrasmall Water‐Soluble and Biocompatible Magnetic Iron Oxide Nanoparticles As Positive and Negative Dual Contrast Agents

2, 3-Dimercaptosuccinic Acid-Modified Iron Oxide Clusters for Magnetic Resonance Imaging

A T1/T2 dual functional iron oxide MRI contrast agent with super stability and low hypersensitivity benefited by ultrahigh carboxyl group density

Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging

Ultrasmall Mn-doped iron oxide nanoparticles with dual hepatobiliary and renal clearances for T1 MR liver imaging

Controlled Synthesis of Shell Cross-Linked Magnetic Micelles for Efficient Liver Mr Imaging

A hepatocyte-targeting nanoparticle for enhanced hepatobiliary magnetic resonance imaging

Development and Characterization of an Antibody-Labeled Super-Paramagnetic Iron Oxide Contrast Agent Targeting Prostate Cancer Cells for Magnetic Resonance Imaging

Casein-Coated Fe5c2 Nanoparticles with Superior R(2) Relaxivity for Liver-Specific Magnetic Resonance Imaging

Delayed hepatic uptake of multi-phosphonic acid poly(ethylene glycol) coated iron oxide measured by real-time Magnetic Resonance Imaging

Superparamagnetic iron oxide nanoparticles stabilized by alginate: Pharmacokinetics, tissue distribution, and applications in detecting liver cancers

SPIO-Loaded Nanostructured Lipid Carriers for T2-weighted Magnetic Resonance Imaging of Hepatocarcinoma

Superparamagnetic PLGA–iron oxide microspheres as contrast agents for dual-imaging and the enhancement of the effects of high-intensity focused ultrasound ablation on liver tissue

Synthesis of well-dispersed aqueous-phase magnetite nanoparticles and their metabolism as an MRI contrast agent for the reticuloendothelial system

Folic acid-conjugated superparamagnetic iron oxide nanoparticles for tumor-targeting MR imaging.

Exerting Enhanced Permeability and Retention Effect Driven Delivery by Ultrafine Iron Oxide Nanoparticles with T1-T2 Switchable Magnetic Resonance Imaging Contrast

Using PEGylated Iron Oxide Nanoparticles with Ultrahigh Relaxivity for MR Imaging of an Orthotopic Model of Human Hepatocellular Carcinoma

Clustered Ultra-Small Iron Oxide Nanoparticles As Potential T1/T2 Dual-Modal Magnetic Resonance Imaging Contrast Agents and Application to Tumor Model

Ultrasound-Triggered Phase Transition Sensitive Magnetic Fluorescent Nanodroplets As a Multimodal Imaging Contrast Agent in Rat and Mouse Model

Specific Targeting of Breast Tumor by Octreotide-Conjugated Ultrasmall Superparamagnetic Iron Oxide Particles Using a Clinical 3.0-Tesla Magnetic Resonance Scanner